Mary J. Fidler, MD

Mary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.

Mary J. Fidler, MD, discusses the utility of dacomitinib (Vizimpro) in patients with EGFR-mutant non–small cell lung cancer.

Mary J. Fidler, MD, discusses overall survival data of the phase III FLAURA trial looking at frontline osimertinib in EGFR-mutant non–small cell lung cancer.

Mary J. Fidler, MD, discusses the results of the phase III RELAY trial in treatment-naïve patients with EGFR-mutant non–small cell lung cancer.

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.